( August 15, 2025, 1:36 PM EDT) -- PHILADELPHIA — A Third Circuit U.S. Court of Appeals panel affirmed a lower court’s ruling that a pharmaceutical company’s shareholder could not opt out of a settlement of a securities fraud class action more than three years after the class opt-out period ended, finding that the shareholder’s continued separate action against the company did not properly show its intent to opt out of the class....